Cargando...
The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma
AIMS: This study quantifies the value of survival gains attributable to novel treatments approved since 2003 for United States (US) patients with relapsed/refractory multiple myeloma (RRMM). METHODS: We estimated the increase in survival attributable to lenalidomide and bortezomib for multiple myelo...
Guardado en:
| Publicado en: | Ther Adv Hematol |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8255558/ https://ncbi.nlm.nih.gov/pubmed/34276923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20406207211027463 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|